摘要
2017年上半年,FDA批准了23个新药,其中新分子实体16种和7种新生物制品。神经系统、肿瘤和皮肤病治疗药物获批数量位居前三位。本系列文章将对这些新药进行介绍和评价,本文主要介绍癌症和内分泌系统疾病治疗新药。
The US FDA approved23new molecular entities and new therapeutic biological products in the first-half of2017.This article provides an update and evaluation of the new drugs approved for the treatment of cancer and endocrine diseases.
作者
孙树森
赵志刚
SUN Shu-sen;ZHAO Zhi-gang(College of Pharmacy and Health Sciences, Western New England University,Springfield, MA 01119,United States;Department of Pharmacy,Beijing Tiantan Hospital Affiliated to Capital Medical University,Beijing 100050,China)
出处
《药品评价》
CAS
2018年第4期3-8,26,共7页
Drug Evaluation
